Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Teligent in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.
Current Consensus is
The current consensus among 0 contributing investment analysts is to n/a stock in Teligent. This rating has held steady since July 2021, when it changed from a Hold consensus rating.
Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.